We are live on ! Find out more
EU

Emory University Portfolio holdings

AUM $267M
1-Year Est. Return 48.26%
This Fund
S&P 500
This Quarter Est. Return
+4.86%
1 Year Est. Return
+48.26%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$52.9M
AUM Growth
+$6.98M
Cap. Flow
+$5.68M
Cap. Flow %
10.75%
Top 10 Hldgs %
100%
Holding
10
New
9
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$1.09M
2
INCY icon
Incyte
INCY
+$1.05M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$1.04M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$1.03M
5
GHDX
Genomic Health, Inc.
GHDX
+$1.02M

Top Sells

Rank Stock Value
1
VWO icon
Vanguard FTSE Emerging Markets ETF
VWO
+$3.58M

Sector Composition

Rank Sector Weight
1 Healthcare 11.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VWO icon
1
Vanguard FTSE Emerging Markets ETF
VWO
$119B
$43.3M 81.83%
1,058,781
-88,119
-8% -$3.58M
ANAC
2
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$1.35M 2.55%
+23,325
New +$990K
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$11.5B
$1.21M 2.29%
+9,715
New +$1.03M
INCY icon
4
Incyte
INCY
$23.4B
$1.17M 2.21%
+12,729
New +$1.05M
BLCM
5
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.05M 1.98%
+4,526
New +$1.09M
SGEN
6
DELISTED
Seagen Inc. Common Stock
SGEN
$1.04M 1.97%
+29,535
New +$1.01M
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$983K 1.86%
+32,167
New +$1.02M
GEVA
8
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$961K 1.82%
+9,854
New +$1.04M
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$4.38B
$957K 1.81%
+29,356
New +$1.01M
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.36B
$886K 1.68%
+98,161
New +$1.02M

Similar funds

CFG
Cambridge Financial Group Columbus, Ohio $267M AUM 31.62% 1-Year Est. Return
PC
Packer & Co Cottesloe, Australia $267M AUM
ALC
Alexander Labrunerie & Co Columbia, Missouri $267M AUM 21.24% 1-Year Est. Return
TWM
TCFG Wealth Management Laguna Niguel, California $267M AUM 39.78% 1-Year Est. Return
IP
Indigo Partners Phoenix, Arizona $267M AUM 9% 1-Year Est. Return
SP
ShawSpring Partners Boston, Massachusetts $268M AUM 28.19% 1-Year Est. Return
EAIC
Empower Annuity Insurance Company Hartford, Connecticut $268M AUM 0.28% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

Emory University's Q1 2015 Portfolio in Review

As of Q1 2015, Emory University held 10 positions worth $52.9M, up 15% from $45.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Emory University deployed $5.68M of net new capital in Q1 2015, opening 9 new positions. Its largest new stake was Bellicum Pharmaceuticals, Inc.: 4,526 shares worth $1.05M.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets.

On the sell side, the largest reduction was Vanguard FTSE Emerging Markets ETF, an estimated $3.58M trimmed.

  • Emory University's largest Q1 2015 buy was Bellicum Pharmaceuticals, Inc.: 4,526 shares worth $1.05M.
  • Emory University's biggest Q1 2015 reduction was Vanguard FTSE Emerging Markets ETF, cutting an estimated $3.58M.
  • Emory University's ten largest holdings make up 100% of its $52.9M portfolio in Q1 2015.
  • Emory University opened 9 new positions and closed 0 in Q1 2015.
  • Emory University's portfolio value rose 15% quarter-over-quarter to $52.9M.

Based on Emory University's 13F filing for Q1 2015, filed 15 May 2015.